Compare TER & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TER | TEVA |
|---|---|---|
| Founded | 1960 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3B | 49.5B |
| IPO Year | 1994 | 1996 |
| Metric | TER | TEVA |
|---|---|---|
| Price | $233.81 | $42.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $415.88 | $50.29 |
| AVG Volume (30 Days) | 3.7M | ★ 6.3M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | 4.52 | ★ 183.45 |
| EPS | ★ 7.08 | 0.02 |
| Revenue | ★ $3,190,024,000.00 | N/A |
| Revenue This Year | $64.02 | N/A |
| Revenue Next Year | $24.80 | $3.34 |
| P/E Ratio | ★ $33.07 | $2,131.00 |
| Revenue Growth | ★ 13.13 | N/A |
| 52 Week Low | $151.52 | $24.01 |
| 52 Week High | $487.91 | $44.57 |
| Indicator | TER | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 54.35 |
| Support Level | $211.91 | $38.55 |
| Resistance Level | $333.44 | $43.34 |
| Average True Range (ATR) | 18.35 | 1.24 |
| MACD | 1.03 | -0.02 |
| Stochastic Oscillator | 30.02 | 44.08 |
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems, and wireless testing for devices. The firm entered the industrial automation market in 2015 and sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies, directly and indirectly, through its products, but its most significant exposure is to semiconductor testing. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.